Introduction
Cobalt, an essential trace element with an atomic number of 27, is a key component of vitamin B12 (i.e. cobalamin) that is involved in the production and regulation of red blood cells, platelet, DNA as well as fatty acid synthesis and energy production. 1, 2 Normal daily dietary intake ranges from 5 to 50 μg with normal plasma concentrations of < 0.2 μg/L. 3 However, excessive cobalt can produce systemic toxicity affecting multiple organ systems. Although not firmly established, it is believed that adverse effects related to cobalt toxicity typically only occur at levels of 7 μg/L or more. 2, 4 In the past, cobalt toxicity was predominantly seen in the form of pulmonary disease in industrial workers who inhaled large amounts of cobalt dust while drilling hard metal or polishing diamonds. 5 More recently, systemic cobalt toxicity has been associated with metal-onmetal (MoM) total hip arthroplasty or the grating down of the cobaltchromium ball (i.e. femoral head) due to retained ceramic particles from a failed ceramic femoral head prosthesis, causing the release of cobalt and chromium metal ions into the systemic circulation. 5, 6 Postarthroplasty metallosis with systemic cobalt toxicity is a rare complication, but the morbidity and mortality related to this complication is extremely high. 1,2 Systemic toxicity associated with excessive levels of cobalt include peripheral neuropathy, vision loss, sensorineural hearing loss, cognitive decline, cardiomyopathy, hypothyroidism, weakness, fatigue and polycythemia (Table 1) .
employed for total hip arthroplasty: MoM, metal-on-polyethylene (MoP), ceramic-on-ceramic (CoC), and ceramic-on-polyethylene (CoP). 19 MoM hip implants were initially introduced in 1950 but lost popularity due to concern for metallosis. In the 1970s, MoP implants became widespread. However, due to polyethylene wear particles playing a role in osteolysis and loosening, alternative materials including CoC and CoP were developed. According to a review published in 2018, the most frequently materials used for total hip arthroplasty were cobalt-chromium alloys due to favorable strength and wear characteristics. 19 We present a case of systemic cobalt toxicity in the setting of multiple total hip arthroplasty revision surgeries resulting in both an optic neuropathy and retinopathy in addition to hearing loss, thyroid dysfunction and cardiac conduction defect. We discuss the underlying pathomechanism of the visual loss from cobalt toxicity and review the debate of metallic hip prosthesis.
Case report
A 59-year-old female presented to our institution for evaluation of bilateral visual loss. Her medical history was notable for deep vein thrombosis and provoked pulmonary embolism after breast reduction surgery in October 2016.
In 2010, she developed left hip pain and underwent hip arthroscopy at an outside institution. Due to the continued hip pain, in March 2011 she underwent a CoC total left hip arthroplasty. Starting in 2013, she noticed a "squeaking" sound in the left hip. By March 2017, while walking, she suddenly heard a "pop" in the left hip and felt the sensation of "walking on shattered glass." She was diagnosed with a catastrophic failure of the hip implant due to ceramic femoral head fracture. Twelve days later, she underwent revision surgery during which she was noted to have extensive debris in the joint from the ceramic particles and a black metallic sludge, attributed to metallic debris produced from the friction between the titanium components of the implant and the fractured ceramic fragments (Fig. 1A) . Extensive debridement was followed by placement of a cobalt-chrome femoral head prosthesis and a highly cross-linked polyethylene acetabular insert.
In the summer of 2017, she began to experience fatigue and hair loss. By December 2017, an audiology evaluation confirmed bilateral high-frequency hearing loss. One month later, she was diagnosed with hypothyroidism and sinus tachycardia. During this time, she also experienced severe headaches, fatigue, as well as numbness and paresthesias in the lower extremities. In May 2018, she was evaluated by a local optometrist for "white, spotty" vision in both eyes. Visual acuity was 20/20 in each eye with a normal fundus. One month later, she presented to a local emergency department for "more spots" in the vision, worsening hearing loss and tachycardia. Visual acuity was 20/250 in the right eye and 20/400 in the left eye. Paraneoplastic serology panel, lumbar puncture, magnetic resonance (MR) imaging and MR angiography of the brain with contrast were all negative or normal. Despite treatment with intravenous corticosteroids and plasma exchange for a possible autoimmune/inflammatory optic neuropathy, the vision in both eyes continued to worsen.
The possibility of cobalt toxicity from her hip prosthesis was suggested by the patient's daughter who coincidentally was watching a Netflix documentary entitled the "Bleeding Edge" and noted the similarities between her mother's symptoms and the patient, who had developed cobalt toxicity after a total hip arthroplasty. 20 On August 2018, serum cobalt level was found to be > 1000 μg/L and chelation therapy with N-Acetylcysteine (NAC) was initiated. She was referred to our institution for urgent surgical consultation and consideration of left hip revision surgery. Repeat cobalt level was 953 μg/mL (normal 0-0.9 μg/ mL), chromium 36.9 μg/mL (normal < 0.3 μg/mL), and titanium 12 μg/mL (normal 0-1 μg/mL). At the time of presentation to our neuro-ophthalmology clinic, she reported only being able to discern light and dark shapes. Visual acuity was 20/600 in the right eye and 20/800 in the left eye. She was unable to recognize any of the Ishihara pseudochromatic plates. Intraocular pressure were 13 mm Hg in both eyes. Pupils were sluggishly reactive to light bilaterally with no relative afferent pupillary defect. Slit-lamp examination revealed trace nuclear sclerotic cataracts and peripheral cortical changes in both eyes. Fundoscopy showed temporal optic disc pallor in both eyes with normal retina and vasculature ( Fig. 2A) . Goldmann visual field testing confirmed bilateral central scotomas (Fig. 2B ). Optical coherence tomography (OCT) demonstrated normal peripapillary retinal nerve fiber layer (pRNFL) thickness in both eyes ( Fig. 3A) , but severe ganglion cell layer-inner plexiform layer (GCLIPL) thinning (Fig. 3B ). Multifocal electroretinography (mfERG) showed decreased tracing amplitudes in both eyes (Fig. 4A) .
A total left hip revision arthroplasty was performed that included insertion of a new acetabular component, exchange of the modular femoral head for one made of ceramic, extensive debridement, and excision of a pseudotumor and synovectomy. Intraoperatively, the surgeon noted extensive black staining of the subcutaneous tissues and when the fascia was incised there was flow of sludge-like black material (Fig. 1B) . Four days after surgery, serum cobalt levels decreased to 378 μg/mL and chromium decreased to 17.5 μg/mL. One month after revision surgery, vision was 20/150 in the right eye and 20/250 in the left eye. Goldmann testing demonstrated a break-up of the central scotomas in both eyes (Fig. 2C) . OCT showed moderate pRNFL thinning in the right eye and severe thinning in the left eye ( Fig. 3C) with persistence of GCLIPL thinning in both eyes (Fig. 3D) . Repeat mfERG demonstrated improvement with an increase in the tracing amplitudes in both eyes (Fig. 4B) . Despite visual improvement, soon after the second revision surgery she was admitted to a local hospital for congestive heart failure due to non-ischemic cardiomyopathy. Nine months after surgery, visual acuity improved to 20/125 in both eyes. Automated visual field testing showed bilateral central scotomas. OCT demonstrated progressive pRNFL and GCLIPL layer thinning but no change in the mfERG.
Discussion
Our patient had findings of both an optic neuropathy and retinopathy secondary to cobalt toxicity. To date there have been only 11 cases published regarding visual loss associated with cobalt toxicity (Table 2) . 6, 8, 9, [11] [12] [13] [14] [15] [16] [17] [18] Males outnumbered females (7 and 4, respectively) with age of the patients ranging from 39 to 71 years. Visual acuity data was not available in 6 patients. Documented improvement in vision was noted in 2 patients, stability in 2 patients and worsening in 1 patient. Cobalt levels ranged from 35 to 1078 μg/L. The diagnosis of cobalt toxicity requires recognizing the potential of hip implant failure to cause visual loss in addition to systemic symptoms. In particular, a detailed surgical history should be obtained in all patients with unexplained visual loss. Ophthalmic findings of cobalt toxicity include decreased visual acuity, dyschromatopsia, central visual field defects, optic atrophy, decreased choroidal perfusion, macular dysfunction, visual evoked potential abnormalities, abnormal ERG, and optic nerve enhancement on MR imaging. 1, 6, 16, 21 Elevated cobalt blood levels will confirm the clinical suspicion. Based on the few cases reported in the literature, the prognosis of ocular cobalt toxicity is variable (Table 2 ). Mild degree of visual acuity improvement can occur in some patients, but other patients have irreversible visual loss. There is no proven treatment for cobalt toxicity aside from decreasing blood cobalt levels by either revising or replacing the failed hip implant as soon as the problem is recognized. As discussed below there is some evidence that NAC can prevent retinal ganglion cell (RGC) apoptosis. Cobalt optic neuropathy and B12 deficiency optic neuropathy share similar ocular and systemic manifestations. 22 This is due to the fact that cobalt is essential for the production of vitamin B12 (i.e cobalamin-a cobalt complex). 23 It is unclear why cobalt excess manifests clinically similar to B12 deficiency. Both cobalt toxic optic neuropathy and B12 deficiency neuropathy are a consequence of disruption in mitochondrial oxidative phosphorylation. 22 Some authors have suggested that cobalt optic neuropathy is secondary to RGC loss resulting from the oxidative stress on the mitochondria caused by the disturbance in the balance between the production and elimination of reactive oxygen species. 5 Apostoli et al. demonstrated severe depletion of RGCs in New Zealand 
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white rabbits receiving 1354-2708 μg/mL of cobalt chloride, while those who were exposed to high levels of both chromium and cobalt had less severe RGC loss, and those receiving only chromium did not have any significant RGC loss. 5 These findings suggest that chromium may actually be protective in the setting of cobalt toxicity and may explain why in some patients there is only mild vision loss and/or vision recovery. Although our patient's titanium levels were also elevated initially, titanium toxicity is rare in humans as it is considered highly biocompatible compared to other metals. 24 To our knowledge, there has been no published reports of elevated titanium levels and vision loss. Furthermore, cobalt exposed rabbits do not only have RGC loss but also have optic nerve axonal swelling and myelin thinning, similar to the pathophysiology of Leber hereditary optic neuropathy (LHON). 5 Additionally, it has been noted that the pRNFL and the pre-laminar portion of the optic nerve may be particularly vulnerable to oxidative stress and apoptosis due to mitochondrial dysfunction. 13 Some have suggested that the mitochondria also plays an important role in photoreceptor function in the setting of LHON. 25 Thus, we propose that our patient's retinopathy is also related to the mitochondrial cytopathy caused by cobalt toxicity. Similar to our patient, Apel et al. showed ERG abnormalities in a patient with known cobalt-chromium toxicity due to a metal prosthesis with improvement after revision surgery. 13 Their case and ours supports the notion that cobalt toxicity can also cause damage to the inner retinal layers. The initial absence of pRNFL thinning in our patient was thought to be from the acute toxic effects of cobalt. During our patient's visual recovery, pRNFL and GCLIPL thickness decreased. The discordance between the GCLPL thinning and near normal pRNFL layer on presentation is suggestive of a mitochondrial cytopathy. This pattern has been observed in some patients with LHON, as well as ethambutol and linezolid toxicity. 26, 27 In the case of ethambutol optic neuropathy, it has been postulated that some axons, particularly in the papillomacular bundle, are able to recover function without undergoing apoptosis. 28 In a case series of five patients, 4 had visual loss from early ethambutol optic neuropathy with normal pRNFL thickness. 29 It has also been demonstrated that tobacco-alcohol induced toxic optic neuropathy can have initial normal pRNFL thickness, thought to be the result of pRNFL edema in the early phase of the pathological process. 30 
Cobalt toxicity and hip prosthesis
It is estimated that 60% of all total hip replacements require revision due to wear-related problems. 7 The mechanical friction between the surfaces can lead to release of metal particles into the hip joint, and absorption into the systemic circulation (Fig. 5) . 7 The prosthesis surfaces can be made of different materials including metal (cobalt-chromium or stainless steel), ceramic or polyethylene. 7, 10 MoP and CoP tend to be less durable due to wear on the polyethylene component. 7 In contrast, MoM (cobalt-chromium alloys) is known to be more durable. 7 However, several studies have now shown that friction between residual microscopic fragments of ceramic and cobalt-chromium metal implants leads to excretion of cobalt and chromium into both the synovial fluid and bloodstream leading to potential systemic toxicity. 2, 4, 8, 17, 18, [31] [32] [33] [34] Bradberry et al. found that the greatest risk of systemic cobalt toxicity occurs in revision surgeries where a cobalt containing prosthesis replaces a failed ceramic prosthesis, rather than from the MoM wear in a first time prosthesis. 7 The main treatment of systemic cobalt toxicity is the revision or removal of the metallic hip prosthesis. 31, 35 Chelation with NAC can be temporarily used until surgery is performed. 31, 35 Yang et al. demonstrated the neuroprotective effects of NAC and that pretreating RGCs can counteract apoptosis by scavenging reactive oxygen species and targeting the hypoxia inducible factor-1 alpha pathway. 35 
Prevention of systemic cobalt toxicity
Because of the risk of developing systemic cobalt toxicity, some experts recommend obtaining whole blood and urine cobalt levels for those patients who previously had CoC prostheses, replaced with cobalt-chromium prosthesis. 31 However, others have pointed out that elevated cobalt levels in otherwise asymptomatic patients may not be an adequate indication for revision. 36 In addition, some have suggested ceramic components should replace failed ceramic prosthesis rather than using cobalt containing metal components. 37, 38 Trebse et al. have recommended "ceramic-onceramic bearings should be preferentially used at revision of fractured ceramic component." 37 They only recommend revision to a MoP if a "thorough synovectomy and pulsatile lavage" can be performed. 37 Others completely oppose the use of polyethylene during revision surgery for a fractured ceramic component citing the potentially deadly effects of this combination due to the embedding of the retained ceramic particles into the polyethylene and subsequent grinding of the metal femoral head. 38 The United States Food and Drug Administration (FDA) currently recommends patients with symptoms suggestive of hip implant failure or with systemic symptoms (skin rash, cardiomyopathy, renal dysfunction, thyroid abnormalities or neurologic such as hearing loss, visual disturbances, or cognitive decline) seek evaluation by an orthopedic surgeon for possible imaging of the hip implant and/or checking serum metal ion levels. Furthermore, the FDA recommends that asymptomatic patients with MoM hip prosthesis follow-up with their orthopedic surgeon every 1-2 years. 39 However, the FDA has noted that there is no scientific evidence for checking levels of metal ions or hip imaging in asymptomatic patients. 39 The United Kingdom, Canada and
Australia have all disseminated public alerts regarding the risk of metallosis in the setting of MoM hip implants. 40, 41 However, at this time there are no specific guidelines regarding the use of polyethylene after ceramic failure.
Conclusions
Systemic cobalt toxicity in the setting of a hip prosthesis can cause significant morbidity and mortality. Based on this report and the few case reports in the literature it appears that ocular cobalt toxicity can involve either the optic nerve, retina or both. It is essential that orthopedic surgeons, ophthalmologists and patients be aware of the local and systemic symptoms of a malfunctioning hip in order to prevent the irreversible detrimental effects of cobalt toxicity.
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